Pamela Hardwick

495 total citations
13 papers, 305 citations indexed

About

Pamela Hardwick is a scholar working on Hematology, Molecular Biology and Oncology. According to data from OpenAlex, Pamela Hardwick has authored 13 papers receiving a total of 305 indexed citations (citations by other indexed papers that have themselves been cited), including 10 papers in Hematology, 7 papers in Molecular Biology and 7 papers in Oncology. Recurrent topics in Pamela Hardwick's work include Multiple Myeloma Research and Treatments (9 papers), Protein Degradation and Inhibitors (5 papers) and Chronic Lymphocytic Leukemia Research (3 papers). Pamela Hardwick is often cited by papers focused on Multiple Myeloma Research and Treatments (9 papers), Protein Degradation and Inhibitors (5 papers) and Chronic Lymphocytic Leukemia Research (3 papers). Pamela Hardwick collaborates with scholars based in United States. Pamela Hardwick's co-authors include Robert F. Cornell, Parameswaran Hari, Rebecca Silbermann, Kelly Godby, Eva Medvedova, Aric C. Hall, Luciano J. Costa, Saurabh Chhabra, Natalie S. Callander and James Omel and has published in prestigious journals such as Journal of Clinical Oncology, Blood and American Journal of Hematology.

In The Last Decade

Pamela Hardwick

11 papers receiving 298 citations

Peers

Pamela Hardwick
Diane E. Durecki United States
Cecilia Rus Italy
S Triolo Italy
Joan Bladé Spain
Laura Montejano Spain
Petra H.M. Westveer Netherlands
Laura Rosiñol Spain
Ammar Al-Zoubi United States
Nola Kennedy Australia
Eugenia Cordero Sweden
Diane E. Durecki United States
Pamela Hardwick
Citations per year, relative to Pamela Hardwick Pamela Hardwick (= 1×) peers Diane E. Durecki

Countries citing papers authored by Pamela Hardwick

Since Specialization
Citations

This map shows the geographic impact of Pamela Hardwick's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Pamela Hardwick with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Pamela Hardwick more than expected).

Fields of papers citing papers by Pamela Hardwick

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Pamela Hardwick. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Pamela Hardwick. The network helps show where Pamela Hardwick may publish in the future.

Co-authorship network of co-authors of Pamela Hardwick

This figure shows the co-authorship network connecting the top 25 collaborators of Pamela Hardwick. A scholar is included among the top collaborators of Pamela Hardwick based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Pamela Hardwick. Pamela Hardwick is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

13 of 13 papers shown
1.
Callander, Natalie S., Rebecca Silbermann, Zhubin Gahvari, et al.. (2024). Combination Regimens in MM Post Autologous Hematopoietic Cell Transplantation (AHCT) to Eliminate MRD Utilizing Iberdomide (COMMANDER): Results of Dose-Finding Component of a Phase 1b/2 Trial. Blood. 144(Supplement 1). 3365–3365. 2 indexed citations
2.
Narkhede, Mayur, Antonio Di Stasi, Lauren Shea, et al.. (2024). Phase 2 Trial of Siltuximab for the Treatment of Cytokine Release Syndrome and Immune Effector Cell Associated Neurotoxicity Related to CAR-T Cell Therapy. Blood. 144(Supplement 1). 3449–3449. 2 indexed citations
3.
Costa, Luciano J., Saurabh Chhabra, Eva Medvedova, et al.. (2023). Minimal residual disease response-adapted therapy in newly diagnosed multiple myeloma (MASTER): final report of the multicentre, single-arm, phase 2 trial. The Lancet Haematology. 10(11). e890–e901. 71 indexed citations
4.
Narkhede, Mayur, Antonio Di Stasi, Susan Bal, et al.. (2023). Interim Analysis of Investigator-Initiated Phase 2 Trial of Siltuximab in Treatment of Cytokine Release Syndrome and Immune Effector Cell Associated Neurotoxicity Related to CAR T-Cell Therapy. Transplantation and Cellular Therapy. 29(2). S133–S134. 7 indexed citations
5.
Bal, Susan, Binod Dhakal, Rebecca Silbermann, et al.. (2022). Impact of autologous hematopoietic cell transplantation on disease burden quantified by next‐generation sequencing in multiple myeloma treated with quadruplet therapy. American Journal of Hematology. 97(9). 1170–1177. 5 indexed citations
6.
7.
Costa, Luciano J., Saurabh Chhabra, Eva Medvedova, et al.. (2021). Daratumumab, Carfilzomib, Lenalidomide, and Dexamethasone With Minimal Residual Disease Response-Adapted Therapy in Newly Diagnosed Multiple Myeloma. Journal of Clinical Oncology. 40(25). 2901–2912. 146 indexed citations
8.
Costa, Luciano J., Saurabh Chhabra, Eva Medvedova, et al.. (2021). OAB-051: Daratumumab, Carfilzomib, Lenalidomide and Dexamethasone (Dara-KRd), autologous transplantation and MRD response-adapted treatment duration and cessation in newly diagnosed Multiple Myeloma (NDMM). Clinical Lymphoma Myeloma & Leukemia. 21. S33–S33. 1 indexed citations
9.
10.
Bal, Susan, Saurabh Chhabra, Natalie S. Callander, et al.. (2021). Biologic Basis of the Impact of Autologous Hematopoietic Cell Transplantation in Multiple Myeloma Treated with Quadruplet Therapy. Blood. 138(Supplement 1). 483–483. 2 indexed citations
11.
Naik, Gurudatta, Ulka N. Vaishampayan, Lisle M. Nabell, et al.. (2020). A phase II trial of regorafenib for advanced urothelial cancer (aUC) following prior chemotherapy.. Journal of Clinical Oncology. 38(6_suppl). 498–498. 1 indexed citations
12.
13.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Diane E. Durecki Breakdown of academic impact, for papers by Cecilia Rus Breakdown of academic impact, for papers by S Triolo Breakdown of academic impact, for papers by Joan Bladé Breakdown of academic impact, for papers by Laura Montejano Breakdown of academic impact, for papers by Petra H.M. Westveer Breakdown of academic impact, for papers by Laura Rosiñol Breakdown of academic impact, for papers by Ammar Al-Zoubi Breakdown of academic impact, for papers by Nola Kennedy Breakdown of academic impact, for papers by Eugenia Cordero
Rankless by CCL
2026